Immune-mediated enterocolitis is associated with immune checkpoint inhibitors: A pharmacovigilance study from the FDA Adverse Event Reporting System (FAERS) database., PMID:40465755
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial., PMID:40450142
Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers., PMID:40447320
Treatment of small cell lung cancer; advances and future prospects., PMID:40446464
[Complete Response Achieved by Gemcitabine+Cisplatin+Durvalumab Therapy for Lymph Node Recurrence of Intraductal Cholangiocarcinoma-A Case Report]., PMID:40420374
Adjuvant Immunotherapy in Microsatellite Instability-High Colon Cancer: A Literature Review on Efficacy, Challenges, and Future Directions., PMID:40415356
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study., PMID:40393235
A platform for SpyCatcher conjugation to native antibodies., PMID:40386161
First-line durvalumab therapy alone or in combination with tremelimumab for metastatic head and neck squamous cell carcinoma: A cost-effectiveness analysis., PMID:40378108
A pharmacovigilance analysis of post-marketing safety of durvalumab., PMID:40360595
Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival., PMID:40349418
Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer., PMID:40349417
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer., PMID:40347676
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study., PMID:40341031
Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON., PMID:40334315
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study., PMID:40331625
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients., PMID:40323277
Revisiting resectability of biliary tract cancers, in the triplet drug therapy era with immune checkpoint inhibitors., PMID:40314879
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)., PMID:40313586
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial., PMID:40311307
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)., PMID:40311183
Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab., PMID:40311014
Tremelimumab plus durvalumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the US payer perspective., PMID:40306910
Durvalumab consolidation after chemoradiotherapy in unresectable stage III non-small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-R., PMID:40300443
Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial., PMID:40298406
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer., PMID:40297626
Conversion Surgery Performed Following Durvalumab Combined With Gemcitabine and Cisplatin in Cholangiocarcinoma: A Case Report., PMID:40294984
A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancer., PMID:40273550
Cost-effectiveness of perioperative nivolumab + neoadjuvant platinum doublet chemotherapy as treatment for resectable non-small cell lung cancer in the United States., PMID:40253592
Durvalumab‑induced type 1 diabetes mellitus in lung adenocarcinoma: A case report and literature review., PMID:40247987
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes., PMID:40245453
Pathological complete response following addition of durvalumab to gemcitabine and cisplatin therapy for intrahepatic cholangiocarcinoma with Lynch syndrome-associated mismatch repair deficiency., PMID:40210796
Factors affecting survival and prognosis in extensive stage small cell lung cancer., PMID:40200252
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial., PMID:40192715
Evaluating the Efficacy and Safety of Durvalumab Plus Radiotherapy in Second-Line Treatment for Advanced Bladder Cancer., PMID:40191869
Early insulin averts hyperglycemic crisis in slow-onset durvalumab-induced checkpoint inhibitor-associated autoimmune diabetes mellitus., PMID:40182155
PD-L1 expression in multiple myeloma myeloid derived suppressor cells., PMID:40180451
Mid-term Combination Immunotherapy and its Effect on the Albumin-Bilirubin Score in Unresectable Hepatocellular Carcinoma., PMID:40155043
Advanced intrahepatic cholangiocarcinoma successfully treated with combined immunotherapy: focusing on the tumor immune microenvironment., PMID:40153223
A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome., PMID:40153010
Immunoscore Predicted by Dynamic Contrast-Enhanced Computed Tomography Can Be a Non-Invasive Biomarker for Immunotherapy Susceptibility of Hepatocellular Carcinoma., PMID:40149284
Immune Checkpoint Inhibitor-associated Pneumonitis: A Narrative Review., PMID:40145913
Prompt initiation of durvalumab and tremelimumab for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B: a phase 2 clinical trial., PMID:40128285
Completion Rates for Patients Undergoing Concurrent Chemoradiotherapy for Stage III Nonsmall Cell Lung Cancer and its Importance in the Era of Consolidation Immunotherapy: A Cohort Study., PMID:40113513
Immune-related adverse events are associated with better event-free survival in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer., PMID:40107153
Current and future perspectives in extensive-stage small-cell lung cancer., PMID:40093978
Epigenetic therapy sensitizes anti-PD-1 refractory head and neck cancers to immunotherapy rechallenge., PMID:40091844
A new standard for HCC: The high stakes of TACE-immunotherapy combinations., PMID:40088884
The evolving landscape of stage III unresectable non-small cell lung cancer "between lights and shadows"., PMID:40086102
Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer., PMID:40081945
For research use only. Not for human or drug use.
